Bridged bicyclic kallikrein inhibitors
US-2016362427-A1 · Dec 15, 2016 · US
Novel lipophilic n-substituted norcantharimide derivatives and uses thereof
US2016145264A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016145264-A1 |
| Application number | US-201414550490-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 21, 2014 |
| Priority date | Nov 21, 2014 |
| Publication date | May 26, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Novel N-substituted norcantharimide derivatives are disclosed herein. The novel N-substituted norcantharimide derivatives are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating cancer, particularly for treating leukemia.
First claim
Opening claim text (preview).
What is claimed is: 1 . A compound of formula (I), Wherein, R is farnesyl or farnesyloxy. 2 . A composition for treating cancer in a subject in need thereof comprising an effective amount of the compound of claim 1 ; and a pharmaceutically acceptable excipient. 3 . The composition of claim 2 , wherein the cancer is selected from the group consisting of leukemia, hepatic cancer, bladder cancer, colon cancer, kidney cancer, ovarian cancer, cervical cancer, endometrial carcinoma, prostate cancer, pancreatic cancer, lung cancer, breast cancer, melanoma, and squamous cell carcinoma (SCC). 4 . The composition of claim 3 , wherein the cancer is leukemia. 5 . The composition of claim 3 , wherein the cancer is hepatic cancer. 6 . A method of treating cancer in a subject in need thereof comprising administering to the subject the composition of claim 2 to suppress and/or inhibit the growth and/or metastasis of the cancer. 7 . The method of claim 6 , wherein in the compound of formula (I), the R is farnesyl. 8 . The method of claim 6 , wherein in the compound of formula (I), the R is farnesyloxy. 9 . The method of claim 6 , wherein the cancer is selected from the group consisting of leukemia, hepatic cancer, bladder cancer, colon cancer, kidney cancer, ovarian cancer, cervical cancer, endometrial carcinoma, prostate cancer, pancreatic cancer, lung cancer, breast cancer, melanoma, and squamous cell carcinoma (SCC). 10 . The method of claim 9 , wherein the cancer is leukemia. 11 . The method of claim 9 , wherein the cancer is hepatic cancer 12 . The method of claim 6 , wherein the subject is a human.
Assignees
Inventors
Classifications
- C07D491/18Primary
Bridged systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016145264A1 cover?
- Novel N-substituted norcantharimide derivatives are disclosed herein. The novel N-substituted norcantharimide derivatives are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating cancer, particularly for treating leukemia.
- Who is the assignee on this patent?
- Taipei Veterans General Hospital, Nat Univ Chiayi, Mackay Memorial Hospital
- What technology area does this patent fall under?
- Primary CPC classification C07D491/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu May 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).